These advantages are largely attributable to ctDNA’s wider dynamic range and shorter half-life, which allow for more rapid and sensitive detection of tumor burden compared to traditional biomarkers, such as CA125 or imaging [26]. The gene discussed is MUC16; the disease is neoplasm.